Clindamycin Orifarm
Lincosamide antibiotic for serious bacterial infections
Clindamycin Orifarm is a prescription lincosamide antibiotic containing clindamycin hydrochloride. It is used to treat serious bacterial infections, including skin and soft tissue infections, bone and joint infections, dental infections, and intra-abdominal infections. Available as 150 mg hard capsules, it works by inhibiting bacterial protein synthesis. This guide covers dosage, side effects, drug interactions, and important safety information based on international medical guidelines.
Quick Facts
Key Takeaways
- Clindamycin Orifarm is a lincosamide antibiotic effective against gram-positive bacteria and anaerobes, prescribed for serious infections including bone, joint, skin, and intra-abdominal infections.
- The standard adult dose is 150–450 mg every 6 hours depending on infection severity; always complete the full course even if symptoms improve.
- The most important risk is Clostridioides difficile-associated diarrhea (CDAD), which can occur during or weeks after treatment—report severe or bloody diarrhea immediately.
- Clindamycin should not be combined with macrolide antibiotics (erythromycin, clarithromycin) due to antagonistic effects at the same ribosomal binding site.
- Store below 30°C in the original packaging protected from light; capsules should be swallowed whole with a full glass of water in an upright position.
What Is Clindamycin Orifarm and What Is It Used For?
Clindamycin Orifarm belongs to the lincosamide class of antibiotics, a group of antimicrobial agents that work by inhibiting bacterial protein synthesis. The active substance, clindamycin hydrochloride, was first developed in the 1960s as a semi-synthetic derivative of lincomycin, and it remains an important antibiotic in modern clinical practice. Clindamycin is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its importance in global healthcare.
The mechanism of action involves binding to the 50S ribosomal subunit of susceptible bacteria, specifically at the 23S rRNA component. This prevents the formation of peptide bonds during protein synthesis, effectively halting bacterial growth. At lower concentrations clindamycin is bacteriostatic (it inhibits growth), while at higher concentrations and against highly susceptible organisms it can be bactericidal (it kills bacteria). This dual action makes it effective against a wide range of pathogens.
Clindamycin demonstrates excellent activity against most aerobic gram-positive cocci, including Staphylococcus aureus (including many methicillin-sensitive strains), Streptococcus pyogenes, Streptococcus pneumoniae, and other streptococcal species. It is also highly effective against a broad spectrum of anaerobic bacteria, including Bacteroides fragilis, Prevotella species, Fusobacterium species, and anaerobic cocci. This anaerobic coverage is one of the primary reasons clindamycin remains clinically valuable.
Approved Indications
Clindamycin Orifarm capsules are indicated for the treatment of serious infections caused by susceptible bacterial organisms. According to international prescribing information and the European Medicines Agency (EMA) guidelines, the main clinical uses include:
- Skin and soft tissue infections: Including cellulitis, wound infections, abscesses, and erysipelas caused by staphylococci and streptococci
- Bone and joint infections: Osteomyelitis and septic arthritis, where clindamycin's excellent bone penetration provides a particular clinical advantage
- Dental and orofacial infections: Periapical abscesses, periodontal infections, and post-surgical dental infections, particularly in patients allergic to penicillin
- Intra-abdominal infections: Including peritonitis and intra-abdominal abscess, typically used in combination with agents active against gram-negative bacteria
- Pelvic infections: Pelvic inflammatory disease, endometritis, and other gynecological infections, often in combination regimens
- Lower respiratory tract infections: Including aspiration pneumonia and lung abscess where anaerobic bacteria play a significant role
Additionally, clindamycin is used off-label in several important clinical scenarios. It is a recommended alternative for patients with penicillin allergy who require treatment for streptococcal or staphylococcal infections. It is also used in the treatment of toxoplasmosis (in combination with pyrimethamine), Pneumocystis jirovecii pneumonia (in combination with primaquine), and malaria (in combination with quinine). The British National Formulary (BNF) and other international guidelines also recommend clindamycin as part of surgical antibiotic prophylaxis in specific clinical settings.
Clindamycin should be reserved for serious infections where other less toxic antibiotics are not appropriate, or where the patient cannot tolerate first-line alternatives. The potential for Clostridioides difficile-associated disease means that clindamycin should not be used for minor or trivial infections. Always follow your prescriber's instructions regarding the specific indication and duration of therapy.
What Should You Know Before Taking Clindamycin Orifarm?
Before beginning treatment with Clindamycin Orifarm, it is essential to provide your healthcare provider with a thorough medical history. Several conditions and circumstances may affect whether clindamycin is appropriate for you or may require dose adjustments and closer monitoring during therapy. The prescribing physician needs this information to make an informed risk-benefit assessment.
Contraindications
You must not use Clindamycin Orifarm if you have a known hypersensitivity (allergy) to:
- Clindamycin – the active substance in Clindamycin Orifarm capsules
- Lincomycin – a structurally related antibiotic in the same drug class
- Any of the inactive ingredients in the capsule formulation, including lactose monohydrate, maize starch, talc, magnesium stearate, gelatin, or titanium dioxide (E171)
Allergic reactions to lincosamide antibiotics can range from mild skin rashes to severe anaphylactic reactions. If you have ever experienced an allergic reaction to either clindamycin or lincomycin in the past, regardless of how mild it was, you should not take this medication.
Warnings and Precautions
Speak with your doctor, pharmacist, or nurse before using Clindamycin Orifarm if any of the following apply to you:
The most serious risk associated with clindamycin use is Clostridioides difficile-associated diarrhea, formerly known as pseudomembranous colitis. This condition occurs when antibiotic use disrupts the normal gut flora, allowing overgrowth of toxin-producing C. difficile bacteria. Symptoms can range from mild diarrhea to life-threatening colitis with toxic megacolon. If you develop severe, persistent, or bloody diarrhea during or up to several weeks after completing clindamycin therapy, contact your doctor immediately. Do not take anti-diarrheal medications (such as loperamide) without medical advice, as these may worsen the condition.
- History of gastrointestinal disease: Inform your doctor if you have a history of diarrhea associated with antibiotic use, inflammatory bowel disease (Crohn's disease or ulcerative colitis), or any previous episode of C. difficile infection. These conditions increase the risk of CDAD.
- Liver impairment: Clindamycin is extensively metabolized in the liver. Patients with moderate to severe hepatic impairment may require dose reduction and regular liver function monitoring. Elevated liver enzymes (transaminases) can occur during treatment.
- Kidney impairment: Although renal excretion accounts for a smaller proportion of clindamycin elimination, acute kidney injury has been reported. If you have pre-existing kidney disease or are taking other nephrotoxic medications, your doctor should monitor renal function. Report any decrease in urine output, swelling of the legs or ankles, shortness of breath, or nausea immediately.
- Atopic conditions: Patients with asthma, eczema, or hay fever may have an increased susceptibility to allergic reactions. Extra caution is warranted in these individuals.
- Prolonged use: Long-term clindamycin therapy may lead to superinfection with resistant organisms, including fungi. Your doctor may perform regular blood tests (complete blood count, liver function, renal function) if treatment extends beyond the typical course.
Severe skin reactions have been reported with clindamycin use, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If you develop a widespread rash, blistering, peeling skin, or fever with skin eruption, discontinue the medication and seek immediate medical attention.
Pregnancy and Breastfeeding
Pregnancy: Clindamycin crosses the placental barrier. While animal studies have not shown direct teratogenic effects, there are limited controlled data in pregnant women. Clindamycin Orifarm should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking this medicine. Your physician will weigh the severity of your infection against the potential risks to your unborn child.
Breastfeeding: Clindamycin is excreted in human breast milk in small amounts. While the concentrations reached in breast milk are generally low, there is a theoretical risk of the infant developing diarrhea or secondary infections (such as oral thrush). The decision to continue breastfeeding during clindamycin therapy should be made in consultation with your healthcare provider, considering the benefit of treatment for the mother and the potential effect on the infant.
Driving and Operating Machinery
Clindamycin Orifarm has no known direct effect on the ability to drive vehicles or operate machinery. However, you should be aware that any illness for which the antibiotic is prescribed, as well as potential side effects such as diarrhea or nausea, could potentially affect your ability to concentrate. Use your own judgment and avoid driving or operating dangerous machinery if you feel unwell.
Lactose Content
Clindamycin Orifarm capsules contain lactose monohydrate as an inactive ingredient. If you have been told by your doctor that you have an intolerance to certain sugars, contact your physician before taking this medicine. Patients with rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
How Does Clindamycin Orifarm Interact with Other Drugs?
Drug interactions can significantly alter the effectiveness or safety profile of clindamycin. Some interactions are pharmacokinetic (affecting absorption, metabolism, or elimination), while others are pharmacodynamic (affecting the drug's mechanism of action). It is critical to inform your doctor, pharmacist, or nurse about all medications you are currently taking, have recently used, or plan to use, including prescription medicines, over-the-counter products, vitamins, and herbal supplements.
Major Interactions
The following drug interactions are considered clinically significant and may require avoidance of the combination, dosage adjustments, or enhanced monitoring:
| Interacting Drug | Category | Effect | Action |
|---|---|---|---|
| Erythromycin | Macrolide antibiotic | Antagonistic – both drugs compete for binding at the 50S ribosomal subunit, reducing efficacy of both | Avoid combination |
| Clarithromycin | Macrolide antibiotic | Antagonistic – same mechanism as erythromycin | Avoid combination |
| Neuromuscular blocking agents (e.g., tubocurarine, pancuronium) | Muscle relaxants | Enhanced neuromuscular blockade – clindamycin has inherent neuromuscular blocking properties that may potentiate these agents | Use with extreme caution; monitor closely in surgical settings |
| Warfarin and other vitamin K antagonists | Anticoagulants | Increased anticoagulant effect and risk of bleeding – clindamycin may alter gut flora that produces vitamin K | Monitor INR frequently; adjust warfarin dose as needed |
| Ciclosporin | Immunosuppressant | Decreased ciclosporin levels – may lead to treatment failure | Monitor ciclosporin levels closely |
Other Notable Interactions
While not necessarily requiring complete avoidance, the following interactions should be considered and discussed with your prescriber:
- Rifampicin: A potent enzyme inducer that may reduce clindamycin levels by accelerating its hepatic metabolism through CYP3A4 induction. Therapeutic drug monitoring or dose adjustment may be necessary.
- Itraconazole and voriconazole: CYP3A4 inhibitors that may increase clindamycin plasma levels. Clinical monitoring for adverse effects is recommended.
- Ritonavir and cobicistat: Strong CYP3A4 inhibitors used in HIV treatment that may increase clindamycin exposure. Dose adjustment may be needed.
- Carbamazepine, phenytoin, and phenobarbital: CYP3A4 inducers used in epilepsy treatment that may decrease clindamycin levels and potentially reduce its effectiveness.
- St. John's Wort (Hypericum perforatum): An herbal product that induces CYP3A4 and may reduce clindamycin efficacy. Avoid concurrent use.
- Kaolin-containing antacids: May significantly reduce oral absorption of clindamycin if taken simultaneously. Separate doses by at least 2 hours.
Clindamycin is frequently used in combination with other antibiotics for mixed infections. It is commonly paired with aminoglycosides (gentamicin) or fluoroquinolones (ciprofloxacin) for intra-abdominal or pelvic infections where anaerobic and gram-negative coverage is needed. These combinations are well-established and generally safe when prescribed by a physician. However, combining clindamycin with macrolide or chloramphenicol antibiotics is not recommended due to overlapping binding sites on the bacterial ribosome.
Food Interactions
Clindamycin Orifarm capsules can be taken with or without food. Food does not significantly affect the absorption of oral clindamycin. However, taking the capsule with a full glass of water and remaining upright (sitting or standing) for at least 30 minutes after ingestion is recommended to reduce the risk of esophageal irritation. There are no known significant food-drug interactions with clindamycin.
What Is the Correct Dosage of Clindamycin Orifarm?
Always take Clindamycin Orifarm exactly as your doctor has prescribed. Do not change the dose or stop taking the medication without consulting your healthcare provider. The dosage depends on the type and severity of infection, the causative organism, the patient's weight and age, and any underlying medical conditions that may affect drug metabolism.
Adults and Elderly
Standard Adult Dosage
The recommended dose for adults is 150–450 mg (1–3 capsules) every 6 hours, depending on the severity of the infection:
- Mild to moderate infections: 150–300 mg every 6 hours
- Severe infections: 300–450 mg every 6 hours
The maximum recommended oral dose is generally 1,800 mg per day (450 mg four times daily). In some severe infections, your doctor may prescribe higher doses or switch to intravenous clindamycin for better tissue concentrations. For dental infections, a common regimen is 150 mg every 6 hours for 5–7 days, or as directed by your dentist or physician.
| Patient Group | Infection Severity | Dose | Frequency |
|---|---|---|---|
| Adults | Mild to moderate | 150–300 mg | Every 6 hours |
| Adults | Severe | 300–450 mg | Every 6 hours |
| Children (≥1 month) | Mild to moderate | 3–6 mg/kg | Every 6 hours |
| Children (≥1 month) | Severe | 6 mg/kg | Every 6 hours |
| Elderly | As per adult dosing | 150–450 mg | Every 6 hours (consider renal/hepatic function) |
Children
The recommended dose for children (aged 1 month and older) is 3–6 mg per kg body weight every 6 hours, depending on infection severity. Your doctor will calculate the appropriate number of capsules based on your child's weight. If your child cannot swallow capsules whole, speak with your doctor or pharmacist about alternative clindamycin formulations, such as oral solution (clindamycin palmitate), which may be more suitable for younger children.
Clindamycin is not recommended for neonates (infants under 1 month of age) without specialist guidance, as the immature hepatic metabolism in this age group may lead to higher and potentially toxic drug levels.
Elderly Patients
No specific dose adjustment is routinely required for elderly patients based solely on age. However, elderly patients are more likely to have reduced hepatic and renal function, and they may be at higher risk for C. difficile-associated diarrhea. Your doctor may choose a conservative dosing approach and monitor liver and kidney function more frequently. If you are taking multiple medications, the risk of drug interactions should also be carefully evaluated.
How to Take the Capsules
Swallow the capsules whole with a full glass of water while sitting or standing upright. Do not lie down for at least 30 minutes after taking the capsule to prevent esophageal irritation. The capsules can be taken with or without food. Do not crush, chew, or open the capsules, as this may affect the drug's stability and your experience of taste.
Missed Dose
If you forget to take a dose, take it as soon as you remember, provided it is still several hours before your next scheduled dose. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. Missing doses may reduce the effectiveness of the antibiotic and increase the risk of developing bacterial resistance.
Overdose
If you take more Clindamycin Orifarm than prescribed, or if a child accidentally ingests the medication, contact your doctor, local emergency department, or poison control center immediately. Bring the medication packaging with you. Symptoms of overdose may include gastrointestinal effects (nausea, vomiting, diarrhea, abdominal pain) and potentially CNS effects. There is no specific antidote for clindamycin overdose; treatment is supportive and symptomatic.
Even if you feel better before the prescribed course is completed, do not stop taking Clindamycin Orifarm prematurely. Stopping antibiotics too early may allow the remaining bacteria to survive, potentially leading to relapse of the infection or the development of antibiotic-resistant bacteria. Always complete the full course as directed by your doctor.
What Are the Side Effects of Clindamycin Orifarm?
Like all medicines, Clindamycin Orifarm can cause side effects, although not everyone experiences them. The frequency and severity of side effects vary among individuals. Most side effects are mild and resolve after treatment is discontinued, but some can be serious and require immediate medical attention. The following information is based on post-marketing surveillance data and clinical trials reported in the product's Summary of Product Characteristics (SmPC) as well as FDA and EMA databases.
- Severe, persistent, or bloody diarrhea (with or without abdominal pain or fever) – may indicate Clostridioides difficile colitis
- Signs of a severe allergic reaction: sudden wheezing, difficulty breathing, swelling of eyelids, face, lips, throat, or tongue; widespread rash or itching
- Yellowing of the skin or whites of the eyes (jaundice) – may indicate liver damage
- Severe skin reactions: widespread rash with blistering, peeling, or ulceration, especially around the mouth, nose, eyes, or genitals
- Decreased urine output, leg or ankle swelling, shortness of breath, or nausea – may indicate acute kidney injury
Common
May affect up to 1 in 10 patients
- Diarrhea (the most frequently reported adverse effect, occurring in up to 20% of patients in some studies)
- Abdominal pain or cramps
- Abnormal liver function test results (elevated transaminases)
Uncommon
May affect up to 1 in 100 patients
- Nausea
- Vomiting
- Maculopapular rash (flat or raised skin eruption)
- Urticaria (hives)
Frequency Not Known
Reported in post-marketing surveillance; exact frequency cannot be estimated
- Clostridioides difficile-associated diarrhea and pseudomembranous colitis
- Vaginal infections (candidiasis)
- Blood disorders: agranulocytosis, leukopenia, neutropenia, thrombocytopenia, eosinophilia
- Anaphylactic reactions and anaphylactoid reactions
- Taste disturbance (dysgeusia) or metallic taste
- Esophagitis and esophageal ulceration
- Jaundice and hepatotoxicity
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- Acute generalized exanthematous pustulosis (AGEP)
- Erythema multiforme
- Exfoliative and bullous dermatitis
- Pruritus (itching)
- Acute kidney injury
Understanding the Risk of C. difficile Infection
Clostridioides difficile (formerly Clostridium difficile) infection is the most clinically important adverse effect associated with clindamycin therapy. This bacterium can proliferate when the normal intestinal microbiome is disrupted by antibiotic use. C. difficile produces toxins that damage the colonic mucosa, leading to a spectrum of disease ranging from mild diarrhea to fulminant pseudomembranous colitis with toxic megacolon, which can be life-threatening.
Risk factors for developing CDAD include advanced age, hospitalization, concurrent use of other antibiotics, use of proton pump inhibitors, and immunosuppression. The risk is not entirely dose-dependent, and CDAD can occur even with short courses of clindamycin. Symptoms may develop during treatment or up to several weeks after completing the course. The FDA and EMA both include a boxed/highlighted warning regarding this risk in the prescribing information for all clindamycin-containing products.
Reporting Side Effects
It is important to report any suspected adverse reactions after the medicine has been authorized. This allows continuous monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report adverse reactions through their national pharmacovigilance system. In the United Kingdom, reports can be made to the MHRA Yellow Card Scheme. In the United States, adverse events can be reported to the FDA MedWatch program. In the European Union, reports can be submitted through the EudraVigilance system or the national competent authority of any member state.
How Should You Store Clindamycin Orifarm?
Proper storage of medications is essential to maintain their effectiveness and safety. Clindamycin Orifarm capsules have specific storage requirements that must be followed to ensure the drug remains stable and potent throughout its shelf life.
- Temperature: Store at or below 30°C (86°F). Do not freeze. Avoid storing in excessively warm or humid environments such as bathrooms.
- Light protection: Keep the capsules in the original blister packaging to protect them from light, as clindamycin is sensitive to light degradation.
- Child safety: Keep this medicine out of the sight and reach of children. Consider using a locked medicine cabinet or a high shelf that children cannot access.
- Expiry date: Do not use the medicine after the expiry date stated on the blister foil and outer carton. The expiry date refers to the last day of that month.
Disposal: Do not throw unused medicines into household waste or pour them down the drain. Return any unused or expired Clindamycin Orifarm capsules to your local pharmacy for safe disposal. Proper pharmaceutical waste disposal helps protect the environment and prevents accidental ingestion by others.
Available Pack Sizes
Clindamycin Orifarm capsules are supplied in aluminum/PVC blister packs. Available pack sizes include 24, 30, 32, 40, or 100 capsules per box. Not all pack sizes may be marketed in all countries. The capsules are white/white hard capsules printed with "CLIN 150" on the capsule body.
What Does Clindamycin Orifarm Contain?
Active Ingredient
Each hard capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin. Clindamycin hydrochloride is the salt form used in oral capsule formulations, which provides good bioavailability and stability. After oral administration, clindamycin hydrochloride is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations reached within 45–60 minutes. The bioavailability of oral clindamycin is approximately 90%, and it is not significantly affected by food intake.
Inactive Ingredients (Excipients)
The inactive ingredients serve various pharmaceutical functions including binding, lubricating, and encapsulating the active substance:
| Component | Ingredient | Function |
|---|---|---|
| Capsule fill | Lactose monohydrate | Filler / diluent |
| Capsule fill | Maize starch | Binder / disintegrant |
| Capsule fill | Talc | Glidant / anti-caking agent |
| Capsule fill | Magnesium stearate | Lubricant |
| Capsule shell | Gelatin | Capsule body and cap |
| Capsule shell | Titanium dioxide (E171) | White colorant / opacifier |
| Printing ink | Shellac, iron oxide black (E172), propylene glycol | Capsule imprint ("CLIN 150") |
Capsule Appearance
Clindamycin Orifarm capsules are white/white hard gelatin capsules marked with "CLIN 150" on the capsule body in black ink. The capsules have a standard size appropriate for oral administration. If you notice any capsules that appear damaged, discolored, or have an unusual odor, do not take them and consult your pharmacist.
Marketing Authorization Holder
The marketing authorization for Clindamycin Orifarm is held by Orifarm Generics A/S, Energivej 15, 5260 Odense S, Denmark. Orifarm Generics is a pharmaceutical company that specializes in the manufacture and distribution of generic medicines across Europe, making essential antibiotics more accessible and affordable.
Frequently Asked Questions
Clindamycin Orifarm is a lincosamide antibiotic prescribed for serious bacterial infections. Its main indications include skin and soft tissue infections (such as cellulitis and abscesses), bone and joint infections (osteomyelitis, septic arthritis), dental infections, intra-abdominal infections, pelvic infections, and lower respiratory tract infections involving anaerobic bacteria. It is particularly useful as an alternative for patients who are allergic to penicillin. The decision to use clindamycin should always be made by a qualified healthcare professional based on the specific type of infection and the susceptibility of the causative bacteria.
The most common side effects are diarrhea (reported in up to 20% of patients), abdominal pain, and abnormal liver function tests. Less common effects include nausea, vomiting, and skin rashes. The most serious potential adverse effect is Clostridioides difficile-associated diarrhea (CDAD), which can range from mild to life-threatening colitis. If you experience severe, persistent, or bloody diarrhea during or after treatment, contact your doctor immediately. Other rare but serious reactions include Stevens-Johnson syndrome, acute kidney injury, and severe allergic reactions.
Clindamycin crosses the placental barrier and should only be used during pregnancy if the doctor determines that the benefit outweighs the potential risk to the fetus. Animal studies have not shown teratogenic effects, but controlled human data are limited. Clindamycin is also excreted in breast milk in small amounts. The decision to breastfeed during treatment should be discussed with your doctor, who will balance the importance of the treatment for you against the possible effects on your baby, such as a theoretical risk of diarrhea or thrush.
Swallow the capsules whole with a full glass of water while sitting or standing upright. Do not lie down for at least 30 minutes after taking the capsule to prevent irritation of the esophagus. The capsules can be taken with or without food. The typical adult dose is 150–450 mg every 6 hours, depending on the severity of the infection. It is crucial to complete the entire prescribed course, even if your symptoms improve before the medication is finished, to prevent the infection from returning and to reduce the risk of antibiotic resistance.
Severe, persistent, or bloody diarrhea during or after clindamycin treatment is a potentially serious warning sign of Clostridioides difficile-associated colitis. You should stop taking the medication and contact your doctor immediately. Do not take over-the-counter anti-diarrheal medications such as loperamide (Imodium), as these can worsen the condition by slowing bowel motility and retaining the bacterial toxins. Stay well-hydrated and seek medical evaluation. This complication can occur during treatment or up to several weeks after completing the antibiotic course.
Yes, clindamycin has several clinically important drug interactions. It should not be combined with macrolide antibiotics (such as erythromycin or clarithromycin) because they compete for the same bacterial binding site, reducing the effectiveness of both drugs. Clindamycin may enhance the effects of neuromuscular blocking agents used during surgery. It can also increase the anticoagulant effect of warfarin, requiring more frequent INR monitoring. CYP3A4 inducers (rifampicin, carbamazepine, St. John's Wort) may reduce clindamycin levels, while CYP3A4 inhibitors (itraconazole, ritonavir) may increase them. Always inform your doctor about all medicines and supplements you take.
References
This article is based on peer-reviewed medical literature, official prescribing information, and international clinical guidelines. All information has been reviewed according to the GRADE evidence framework.
- European Medicines Agency (EMA). Clindamycin – Summary of Product Characteristics. www.ema.europa.eu. Accessed January 2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. www.who.int.
- British National Formulary (BNF). Clindamycin. National Institute for Health and Care Excellence (NICE). bnf.nice.org.uk. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Cleocin (Clindamycin Hydrochloride) Capsules – Prescribing Information. www.accessdata.fda.gov.
- McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases. 2018;66(7):e1–e48. doi:10.1093/cid/cix1085
- Smieja M. Current indications for the use of clindamycin: A critical review. Canadian Journal of Infectious Diseases. 1998;9(1):22–28. doi:10.1155/1998/538090
- Brook I. Spectrum and treatment of anaerobic infections. Journal of Infection and Chemotherapy. 2016;22(1):1–13. doi:10.1016/j.jiac.2015.10.010
- Spizek J, Rezanka T. Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications. Biochemical Pharmacology. 2017;133:20–28. doi:10.1016/j.bcp.2016.12.001
- World Health Organization (WHO). WHO Model Formulary. www.who.int. 2023 Edition.
- Leffler DA, Lamont JT. Clostridium difficile Infection. New England Journal of Medicine. 2015;372(16):1539–1548. doi:10.1056/NEJMra1403772
Editorial Team
This article was created and medically reviewed by the iMedic Medical Editorial Team, comprising specialist physicians in infectious disease, clinical pharmacology, and internal medicine with documented academic backgrounds and clinical experience.
Written by licensed medical professionals with expertise in antimicrobial pharmacology and infectious disease management. All content follows international prescribing guidelines and evidence-based medicine principles.
Reviewed by the iMedic Medical Review Board – an independent panel of board-certified physicians who verify clinical accuracy, dosage information, drug interactions, and safety data against current EMA, FDA, and WHO guidelines.
All iMedic medicine articles adhere to the following standards: Evidence Level 1A (systematic reviews and RCTs), GRADE evidence framework, no commercial funding or pharmaceutical sponsorship, regular updates following new guideline publications, and full compliance with international medical editorial standards. Our content is independent, unbiased, and focused solely on providing accurate, accessible health information.